Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Comparative drug screening in NUT midline carcinoma

The NUT midline carcinoma (NMC) is a rare but fatal cancer for which systematic testing of therapy options has never been performed.

Research

Birthweight and childhood cancer: Preliminary findings from the international childhood cancer cohort consortium (I4C)

Background Evidence relating childhood cancer to high birthweight is derived primarily from registry and case-control studies.

Research

Lessons from 50 years of curing childhood leukaemia

One of the great success stories of modern medicine is undoubtedly the remarkable improvement in outcome for childhood cancer, achieved through the work of...

Research

Basal cell carcinomas on sun-protected vs. sun-exposed body sites: A comparison of phenotypic and environmental risk factors

There are indications that risk factors for BCC may differ according to the anatomic site of the tumour but this is not well understood.

News & Events

The goal of Project Childrens' Cancer is to discover new, less toxic therapies

The goal of Project Children's Cancer is to discover new therapies that are more effective and less toxic to fight aggressive cancers in babies and children.

News & Events

More research needed into mums smoking and childhood brain tumours

Researchers from Perth's Telethon Institute are calling for further investigation into a potential link between maternal smoking and childhood brain tumours.

Research

A New Era for PPARγ: Covalent Ligands and Therapeutic Applications

Peroxisome proliferator-activated receptor γ (PPARγ) is a prominent ligand-inducible transcription factor involved in adipocyte differentiation, glucose homeostasis, insulin sensitivity, inflammation, and cell proliferation, making it a therapeutic target for diabetes, metabolic syndrome, autoimmune diseases, and cancer. 

Research

IDH mutant high-grade gliomas

Gliomas are the most common type of malignant primary central nervous system (CNS) tumors, resulting in significant morbidity and mortality in children and adolescent and young adult (AYA) patients. The discovery of mutations in isocitrate dehydrogenase (IDH) genes has dramatically changed the classification and understanding of gliomas.  IDH mutant gliomas have distinct clinical, pathological, and molecular features including a favorable prognosis and response to therapy compared to their wildtype counterparts.

Research

Long-Term Outcome of Young Infants With Suspected Neuroblastoma following Observation as Primary Therapy: A Report From the Children's Oncology Group

Several studies have established that patients with localized perinatal neuroblastoma can be safely observed; however, long-term outcomes have not been previously reported. We evaluated long-term outcomes of infants with suspected perinatal neuroblastoma enrolled on the Children's Oncology Group ANBL00P2, which included an expectant observation approach.